Exercised option to acquire exclusive development and commercialization rights for lucerastat in Japan and certain APAC territories, including Korea and Taiwan, and will advance development in the designated territories. Paid an initial upfront of 7 million Swiss francs and will cooperate with global Phase 3 advancement.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nxera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4565-20261028-01.pdf","jir_short_summary":"Exercised option to acquire exclusive development and commercialization rights for lucerastat in Japan and certain APAC territories, including Korea and Taiwan, and will advance development in the designated territories. Paid an initial upfront of 7 million Swiss francs and will cooperate with global Phase 3 advancement.","jir_summary":"### Overview of the Partnership\nNxera Pharma Co., Ltd. has exercised an option to license lucerastat from Idorsia Pharmaceuticals, acquiring exclusive development and commercialization rights for lucerastat in certain APAC territories including Japan, South Korea and Taiwan. An upfront payment of 7 million CHF will be made, and Nxera Pharma will cooperate with the advancement of the global Phase 3 program. Idorsia will receive royalties based on net sales in the designated territories. The trials are part of the global Phase 3 program including FAB-KLEAR, and Nxera Pharma will manage clinical development operations in Japan.\n\n### Impact on Business Strategy and Future Outlook\nLucerastat is believed to potentially slow Fabry disease progression by inhibiting Gb3 production, and Phase 3 data suggests it may delay deterioration of renal function. Under a global development strategy aligned with FDA\/EMA considerations, participation in the approval-seeking program is intended to expand Nxera Pharma\u2019s portfolio in the rare disease area across Japan and APAC.","jir_financial_highlights":"Upfront Payment: 7 million CHF (approx. 1,334 million yen) (Unknown)\nTerritories: Japan, South Korea, Taiwan and certain other Asia-Pacific territories (excluding China) (Unknown)\nRoyalties: Will receive royalties based on net sales (Unknown)","jir_category":"","jir_hashtags":"#NxeraPharmaPartnership, #lucerastatLicense, #FabryDisease, #APACStrategy","jir_key_figures":"Upfront payment: 7 million CHF (approx. 1,334 million yen)\nTerritories: Japan, South Korea, Taiwan and certain other Asia-Pacific territories (excluding China)\nLong-term outlook: Cooperation in the global Phase 3 trial program and development toward regulatory submissions","jir_meta_title":"Nxera Pharma Announces Exclusive APAC License Agreement for lucerastat with Idorsia\uff5cOctober 2026","jir_meta_description":"Nxera Pharma has acquired exclusive development and commercialization rights for lucerastat in parts of APAC including Japan, South Korea and Taiwan. The deal includes a 7 million CHF upfront payment and cooperation on global Phase 3 trials. Overview of development strategy toward regulatory submissions and market expansion.","jir_og_title":"Nxera Pharma Concludes Exclusive APAC License Agreement for lucerastat with Idorsia","jir_og_description":"Nxera Pharma has obtained development and commercialization rights for lucerastat in APAC. Summary of the agreement including a 7 million CHF upfront payment and cooperation on global Phase 3 advancement.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-135680","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n